Concise stereocontrolled routes to fumagillol, fumagillin, and TNP-470

Chirality

Volumn 15, Issue 2, 2003, Pages 156-166

  Vosburg, David A ^a   Weiler, Sven ^a   Sorensen, Erik J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis inhibitors; Chiral auxiliary; Conjugate addition; Diastereo selective cycloaddition; Hetero Claisen rearrangement; Natural products; Sharpless epoxidation; Total synthesis

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; FUMAGILLOL; FUMAGILLOL CHLOROACETYLCARBAMATE; NATURAL PRODUCT;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHIRALITY; CLAISEN CONDENSATION; CONJUGATION; CYCLOADDITION; DIASTEREOISOMER; DIELS ALDER REACTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; SHARPLESS EPOXIDATION; STEREOCHEMISTRY; SYNTHESIS;

BICYCLO COMPOUNDS; CYCLOHEXANES; FATTY ACIDS, UNSATURATED; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; SESQUITERPENES; STEREOISOMERISM;

EID: 0037261488     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10181     Document Type: Article

References (108)

1. Hanson FR, Eble E. An antiphage agent isolated from Aspergillus sp. J Bact 1949;58:527-529.
2. (a) McCowen MC, Callender ME, Lawlis JF Jr. Fumagillin (H-3), a new antibiotic with amebicidal properties. Science 1951;112:202-203.
3. (b) Katznelson H, Jamieson CA. Control of Nosema disease of honeybees with fumagillin. Science 1952;115:70-71.
4. (c) Killough JH, Magill GB, Smith RC. The treatment of amebiasis with fumagillin. Science 1952;115:71-72.
5. (a) Tarbell DS, Carman RM, Chapman DD, Huffinan KR, McCorkindale NJ. The structure of fumagillin. J Am Chem Soc 1960;82:1005-1007.
6. (b) Tarbell DS, Carman RM, Chapman DD, Cremer SE, Cross AD, Huffman KR, Kunstmann M, McCorkindale NJ, McNally JG Jr, Rosowsky A, Varino FHL, West RL. The chemistry of fumagillin. J Am Chem Soc 1961;83:3096-3113, and references therein.
7. (c) Turner JR, Tarbell DS. The stereochemistry of fumagillin. Proc Natl Acad Sci USA 1962;48:733-735.
8. McCorkindale NJ, Sime JG. The configuration of fumagillin. Proc Chem Soc 1961;331.
9. Wilkins JH, Joshi N, Margolis TP, Cevallos V, Dawson CR. Microsporidial keratoconjunctivitis treated successfully with a short course of fumagillin. Eye 1994;8:703-704.
10. Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, Milhous WK, Chiang PK. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci2002;9:34-40.
11. (a) Molina JM, Derouin F. Pharmaceutical preparations containing fumagillol and derivatives thereof for treatment of intestinal infections. PCT. Int. Appl. WO 9630010, CA., 125, 309073.
12. (b) Coyle C, Kent M, Tanowitz HB, Wittner M, Weiss LM. TNP-470 is an effective antimicrosporidial agent. J Infect Dis 1998;177:515-518.
13. (c) Molina J-M, Goguel J, Sarfati C, Michiels J-F, Desportes-Livage I, Balkan S, Chastang C, Cotte L, Maslo C, Struxiano A, Derouin F, Decazes J-M. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 2000;14:1341-1348.
14. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
15. (a) Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285:1182-1186.
16. (b) Folkman J. Clinical applications of research on angiogenesis. New Engl J Med 1995;333:1757-1763.
17. (c) Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
18. (d) Giannis A, Rübsam F. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: new drugs in cancer therapy. Angew Chem Int Ed Engl 1997;36:588-590.
19. (e) Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
20. (f) Zhang H-T, Harris AL. Anti-angiogenic therapies in cancer clinical trials. Exp Opin Invest Drugs 1998;7:1629-1655.
21. (g) Brower V. Tumor angiogenesis-new drugs on the block. Nature Biotech 1999;17:963-968.
22. (a) Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-2570.
23. (b) Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-216.
24. (c) Bergers G, Javaherian K, Lo K-M, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812.
25. (d) Offodile R, Walton T, Lee M, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 1999;85:51-53.
26. (e) Milkowski DM, Weiss RA. TNP-470. In: Teicher BA, editor. Antiangiogenic agents in cancer therapy. Totowa, NJ: Humana; 1999. p 385-398.
27. (a) Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993;53:5233-5236.
28. (b) Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen Y-N, Brem H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 1994;57:920-925.
29. (c) Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)-fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-5147.
30. (a) Sigg HP, Weber HP. Isolation and structural elucidation of ovalicin. Helv Chim Acta 1968;51:1395-1408.
31. (b) Bollinger P, Sigg HP, Weber HP. Structure of ovalicin. Helv Chim Acta 1973;56:819-830.
32. (a) Sin N, Meng L, Wang MQW, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997;94:6099-6103.
33. (b) Griffith EC, Su Z, Turk BE, Chen S, Chang Y-H, Wu Z, Biemann K, Liu JO. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AMG-1470 and ovalicin. Chem Biol 1997;4:461-471.
34. (a) Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998;282:1324-1327.
35. (b) Lowther WT, McMillen DA, Orville AM, Matthews BW. The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc Natl Acad Sci USA 1998;95:12153-12157.
36. (c) Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang Y-H, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998;95:15183-15188.
37. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 1998;58:3751-3756.
38. (a) Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001;159:721-731.
39. (b) Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994;54:3407-3412.
40. (c) Turk BE, Su Z, Liu JO. Synthetic analogs of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 1998;6:1163-1169.
41. (d) Wemert N, Stanjek A, Kiriakidis S, Hügel A, Jha HC, Mazitschek R, Giannis A. Inhibition of angiogenesis in vivo by ets-1 antisense oligonucleotides - inhibition of Ets1 transcription factor expression by the antibiotic fumagillin. Angew Chem Int Ed 1999;38:3228-3231.
42. (e) Tudan C, Jackson JK, Pelech SL, Attardo G, Burt H. Selective inhibition of protein kinase C, mitogen-activated protein kinase, and neutrophil activation in response to calcium pyrophosphate dihydrate crystals, formyl-methionyl-leucyl-phenylalanine, and phorbol ester by O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470; TNP-470). Biochem Pharmacol 1999;58:1869-1880.
43. (f) Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000;77:465-473.
44. WAF1/CIP1. Proc Natl Acad Sci USA 2000;97:6427-6432.
45. Hatanaka H, Kino T, Hashimoto M, Tsurumi Y, Kuroda A, Tanaka H, Goto T, Okuhara M. FR65814, a novel immunosuppressant isolated from a Penicillium strain. Taxonomy, fermentation, isolation, physicochemical and biological characteristics and structure assignment. J Antibiot 1988;41:999-1008.
46. (a) Birch AJ, Hussain SF. Studies in relation to biosynthesis. XXXVIII. A preliminary study of fumagillin. J Chem Soc, C 1969;1473-1474.
47. 13C-acetate into the fungal sesquiterpene ovalicin. Tetrahedron Lett 1974;15:4417-4420.
48. (c) Cane DE, Levin RH. Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. I. Ovalicin. J Am Chem Soc 1975;97:1282-1284.
49. (d) Cane DE, Levin RH. Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. II. Ovalicin and the use of doubly labeled mevalonate. J Am Chem Soc 1976;98:1183-1188.
50. (e) Nozoe S, Kobayashi H, Morisaki N. Isolation of β-trans-bergamotene from Aspergillus fumigatus, a fumagillin producing fungi. Tetrahedron Lett 1976;17:4625-4626.
51. (f) Cane DE, King GGS. The biosynthesis of ovalicin: isolation of β-transbergamotene. Tetrahedron Lett 1976;17:4737-4740.
52. (g) Cane DE, Buchwald SL. Application of deuterium magnetic resonance to biosynthetic studies. 1. Biosynthesis of ovalicin. J Am Chem Soc 1977;99:6132-6134.
53. (h) Cane DE, McIlwaine DB. The biosynthesis of ovalicin from β-trans-bergamotene. Tetrahedron Lett 1987;28:6545-6548.
54. (a) Young ST, Turner JR, Tarbell DS. Synthetic studies in the fumagillin series. J Org Chem 1963;28:928-932.
55. (b) Hayward EC. Synthetic studies in the fumagillin series. Ph.D. Thesis, University of Rochester, 1968.
56. (c) Peters CA. Studies directed toward the total synthesis of 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro [2.5] octan-6-ol obtained from mild saponification of fumagillin. Ph.D. Thesis, University of Oklahoma, 1969.
57. (d) Brannigan LH. Syntheses in the fumagillin series. Ph.D. Thesis, Vanderbilt University, 1970.
58. (e) Büchi G, Powell JE Jr. Claisen rearrangement of 3,4-dihydro-2H-pyranylethylenes. J Am Chem Soc 1970;92:3126-3133.
59. (f) O'Connor JF. Synthetic studies in the fumagillin series. Ph.D. Thesis, University of Rochester, 1971.
60. (a) Corey EJ, Snider BB. A total synthesis of (±)-fumagillin. J Am Chem Soc 1972;94:2549-2550.
61. (b) Snider BB. The total synthesis of racemic fumagillin; a new synthesis of prostaglandins. Ph.D. Thesis, Harvard University, 1973.
62. Kim D, Ahn SK, Bae H, Choi WJ, Kim HS. An asymmetric total synthesis of (-)-fumagillol. Tetrahedron Lett 1997;38:4437-4440.
63. Vosburg DA, Weiler S, Sorensen EJ. A concise synthesis of fumagillol. Angew Chem Int Ed 1999;38:971-974.
64. Taber DF, Christos TE, Rheingold AL, Guzei IA. Synthesis of (-)-fumagillin. J Am Chem Soc 1999;121:5589-5590.
65. Hutchings M, Moffat D, Simpkins NS. A concise synthesis of fumagillol, Synlett 2001;661-663.
66. Boiteau J-G, Van de Weghe P, Eustache J. A new, ring closing metathesis-based synthesis of (-)-fumagillol. Org Lett 2001;3:2737-2740.
67. (a) Corey EJ, Dittami JP. Total synthesis of (±)-ovalicin. J Am Chem Soc 1985;107:256-257.
68. (b) Bath S, Billington DC, Gero SD, Quiclet-Sire B, Samadi M. Total synthesis of (-)-ovalicin from L-quebrachitol. J Chem Soc, Chem Commun 1994;1495-1496.
69. (c) Corey EJ, Guzman-Perez A, Noe MC. Short enantioselective synthesis of (-)-ovalicin, a potent inhibitor of angiogenesis, using substrate-enhanced catalytic asymmetric dihydroxylation. J Am Chem Soc 1994;116:12109-12110.
70. (d) Barton DHR, Bath S, Billington DD, Gero SD, Quiclet-Sire B, Samadi M. Total synthesis of (-)-ovalicin and analogues from L-quebrachitol. J Chem Soc, Perkin Trans 1 1995;1551-1558.
71. (e) Barco A, Benetti S, De Risi C, Marchetti P, Pollini GP, Zanirato V. Enantio-selective formal synthesis of (-)-ovalicin using quinic acid as a chiral template. Tetrahedron: Asymm 1998;9:2857-2864.
72. (a) Amano S, Ogawa N, Ohtsuka M, Ogawa S, Chida N. Total synthesis and absolute configuration of FR65814. Chem Commun 1998;1263-1264.
73. (b) Amano S, Ogawa N, Ohtsuka M, Chida N. Chiral and stereoselective total synthesis of novel immunosuppressant FR65814 from D-glucose. Tetrahedron 1999;55:2205-2224.
74. Vosburg DA. Synthesis of Fumagillin and (+)-FR182877. Ph.D. Thesis, Scripps Research Institute, 2002.
75. Kallmerten J. [1,2] Sigmatropic rearrangements. In: Helmchen G, Hoffmann RW, Mulzer J, Schaumann E, editors. Stereoselective synthesis, vol. 6. New York: Thieme; 1996. p 3810-3832.
76. (a) Maruoka K, Hasegawa M, Yamamoto H, Suzuki K, Shimazaki M, Tsuchihashi G. Epoxy silyl ether rearrangements: a new, stereoselective approach to the synthesis of β-hydroxy carbonyl compounds. J Am Chem Soc 1986;108:3827-3829.
77. 3-hybridized carbon atoms. J Org Chem 1993;58:5944-5951.
78. Marui S, Itoh F, Kozai Y, Sudo K, Kishimoto S. Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols. Chem Pharm Bull 1992;40:96-101.
79. Van Rheenen V, Kelly RC, Cha DY. An improved catalytic osmium tetroxide oxidation of olefins to cis-1,2-glycols using tertiary amine oxides as the oxidant. Tetrahedron Lett 1976;25:1973-1976.
80. Langenbeck W, Godde O, Weschky L, Schaller R. Diene syntheses with derivatives of 1-amino-1,3-butadiene. Ber Dtsch Chem Ges 1942;75:232-236.
81. 1-Diethylamino-1,3-butadiene can be prepared on a large scale in one step from diethylamine and crotonaldehyde; see: Hünig S, Kahanek H. Diene syntheses with 1-diethylaminobutadiene and thermal cleavage of the adducts, Chem Ber 1957;90:238-245.
82. For the use of Li(2-thienyl)CuCN, see: Lipshutz BH, Koerner M, Parker DA. 2-Thienyl(cyano)copperlithium. A lower order, stable "cuprate in a bottle" precursor to higher order reagents. Tetrahedron Lett 1987;28:945-948.
83. Vinyl bromide 18 was prepared by a slight modification of Corey's excellent one-flask procedure; see: Corey EJ, Lee J, Roberts BE. The application of the Shapiro reaction to the stereoselective synthesis of E-trisubstituted olefins for cation-olefin cyclization by three component coupling. Tetrahedron Lett 1997;38:8915-8918. See also reference 26a.
84. 2, followed by fluoride-induced cleavage of the crude silyl enol ethers.
85. For a review of the conjugate addition chemistry of organocuprates, see: Lipshutz BH, Sengupta S. Organocopper reagents: substitution, conjugate addition, carbo/metallocupration, and other reactions. Org React 1992;41:135-631.
86. (a) Han G, Hruby VJ. A study of conjugate addition to a γ,δ-dioxolanyl-α,β-unsaturated ester. Tetrahedron Lett 2001;42:4281-4283.
87. (b) Yechezkel T, Ghera E, Ramesh NG, Hassner A. Stereochemistry. 88. Asymmetric synthesis of substituted cyclopentanes via Michael initiated ring closure reactions. Tetrahedron: Asymm 1996;7:2423-2436.
88. (c) Leonard J, Mohialdin S, Reed D, Ryan G, Swain PA. Stereoselective conjugate addition of organolithium and organocopper reagents to δ-oxygenated α,β-unsaturated carbonyl systems derived from glyceraldehyde acetonide. Tetrahedron 1995;51:12843-12858.
89. 2, dihydroxylation, and hydroboration. Trapping aldehyde enolates with Davis's oxaziridine produced the undesired diastereomer in low yield.
90. 2, dihydroxylation, and hydroboration. Trapping aldehyde enolates with Davis's oxaziridine produced the undesired diastereomer in low yield.
91. House HO, Richey FA Jr. Use of ketoxime derivatives to prepare α-acetoxy ketones. J Org Chem 1969;34:1430-1439.
92. Cummins CH, Coates RM. α-Oxygenation of aldehydes and cyclic ketones by acylafion-rearrangement of nitrones. J Org Chem 1983;48:2070-2076.
93. Johnson F. Allylic strain in six-membered rings. Chem Rev 1968;68:375-413.
94. House HO, Lubinkowski J, Good JJ. Some stereochemical aspects of the Claisen rearrangement of allyl vinyl ethers. J Org Chem 1975;40:86-92.
95. Sharpless KB, Michaelson RC. High stereo- and regioselectivities in the transition metal catalyzed epoxidafions of olefinic alcohols by tertbutyl hydroperoxide. J Am Chem Soc 1973;95:6136-6137.
96. See reference 27 for a closely related transformation that was described while our studies were under way.
97. See reference 20; this is a slight modification of a procedure employed in Corey and Snider's pioneering synthesis of fumagillin.
98. McComsey DF, Maryanoff BE. Improved synthesis of pseudo-β-D-fructopyranose, a carboxylic monosaccharide from (-)-quinic acid. J Org Chem 1994;59:2652-2654.
99. Wang Z-M, Kakiuchi K, Sharpless KB. Osmium-catalyzed asymmetric dihydroxylation of cyclic cis-disubstituted olefins. J Org Chem 1994;59:6895-6897.
100. Murphy JP, Nieuwenhuyzen M, Reynolds K, Sarma PKS, Stevenson PJ. Chiral dienamides - substrates for asymmetric synthesis of amido cyclohexenes. Tetrahedron Lett 1995;36:9533-9536.
101. McAlonan H, Murphy JP, Nieuwenhuyzen M, Reynolds K, Sarma PKS, Stevenson PJ, Thompson N. 4-Phenyloxazolidin-2-ones and isoindolin-1-ones: chiral auxiliaries for Diels-Alder reactions of N-substituted 1,3-dienes. J Chem Soc, Perkin Trans 1 2002;13:69-79. Rawal has reported a siloxy-substituted derivative of this chiral diene; see: Janey JM, Iwama T, Kozmin SA. Racemic and asymmetric Diels-Alder reactions of 1-(2-oxazolidinon-3-yl)-3-siloxy-1,3-butadienes. J Org Chem 2000;65:9059-9068.
102. McAlonan H, Murphy JP, Nieuwenhuyzen M, Reynolds K, Sarma PKS, Stevenson PJ, Thompson N. 4-Phenyloxazolidin-2-ones and isoindolin-1-ones: chiral auxiliaries for Diels-Alder reactions of N-substituted 1,3-dienes. J Chem Soc, Perkin Trans 1 2002;13:69-79. Rawal has reported a siloxy-substituted derivative of this chiral diene; see: Janey JM, Iwama T, Kozmin SA. Racemic and asymmetric Diels-Alder reactions of 1-(2-oxazolidinon-3-yl)-3-siloxy-1,3-butadienes. J Org Chem 2000;65:9059-9068.
103. (a) Kuhn R, Grundmann C. A new way of synthesizing polyenes; synthesis of hexatriene-1,6- and octatetraene-1,8-dicarboxylic acids. Chem Ber 1936;69:1757-1765.
104. (b) Schenck JR, Hargie MP, Tarbell DS, Hoffman P. Decatetraenedioic acid, a fumagillin degradation product. J Am Chem Soc 1953;75:2274.
105. Poss CS, Schreiber SL. Two-directional chain synthesis and terminus differentiation. Acc Chem Res 1994;27:9-17.
106. (a) Kossmehl G, Bohn B. Simple synthesis of mucondialdehyde. Chem Ber 1974;107:710-711.
107. (b) Golding BT, Kennedy G, Watson WP. Simple syntheses of isomers of muconaldehyde and 2-methylmuconaldehyde. Tetrahedron Lett 1988;29:5991-5994.
108. Paterson I, Yeung K-S, Smaill JB. The Horner-Wadsworth-Emmons reaction in natural products synthesis: expedient construction of complex (E)-enones using barium hydroxide. Synlett 1993;774-776.